SCHEMBL771494

SCHEMBL771494

O=C(CN1C(=O)c2cccc(F)c2C1=O)N1CCC2CCCC=C2C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 5/20 0.43
MAPT P10636 2/20 0.43
HSD17B10 Q99714 2/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 2/20 0.38
GAA P10253 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PABPC1 P11940 1/20 0.36
HTT P42858 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771256 0.90 MAPK1 (0.50) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL770464 0.89 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL771359 0.89 SMN1; SMN2 (0.52) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL771252 0.88 HSD17B10 (0.53) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL769981 0.82 HSD17B10 (0.40) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL770404 0.80 HSD17B10 (0.40) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL771557 0.79 HSD17B10 (0.38) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL771730 0.78 SMN1; SMN2 (0.52) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL770981 0.77 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTHSD17B10HPGD
SCHEMBL770301 0.77 MAPK1 (0.64) ALDH1A1MAPTHSD17B10HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885KDM4E 4105/4885MAPT 618/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885KDM4E 4127/4885MAPT 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.